Anonymous User
Login / Registration

a hepatologie

Gastroenterology and Hepatology

Gastroent Hepatol 2011; 65(2): 70-74.

Influence of albuminemia on the pharmacokinetics of infliximab in patients with inflammatory bowel diseases

Karin Malíčková  1,2, Martin Bortlík  1,3,4, Dana Ďuricová  1, Helena Brodská  , Naděžda Machková  1, Ivana Janatková  , Tomáš Zima  , Milan Lukáš  1

+ Affiliation


Purpose of the study: To analyse infliximab and albumin serum levels in different stages of the biological treatment of patients with inflammatory bowel diseases (IBD).

Methods: We examined the serum trough levels of infliximab and albuminemia in 85 patients with IBD in weeks 2 and 14 of biological treatment with infliximab.

Results: In week 2, infliximab was detected in the sera of 34 patients (40%) and in week 14 in 44 patients (52%). Serum infliximab trough levels were significantly lower in week 2 than in week 14 (p = 0.0138). Likewise, levels of albumin in week 2 were significantly lower than in week 14 (p = 0.0002). In patients with detectable serum infliximab trough levels (concentration > 3 μg/ml), albuminemia was significantly higher than in patients with undetectable serum infliximab levels, regardless of the biological treatment stage. The correlation between serum infliximab levels and albuminemia was significantly positive (r = 0.39, p < 0.0001).

Conclusions: Levels of both infliximab and albumin rise during biological treatment of IBD. We confirmed a significant positive correlation between albumin and infliximab serum levels, suggesting the theoretical possibility of using serum albumin to predict infliximab pharmacokinetics.


biological therapy, inflammatory bowel disease, infliximab

To read this article in full, please register for free on this website.

Benefits for subscribers

Benefits for logged users

Credited self-teaching test